191 related articles for article (PubMed ID: 10498451)
1. Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease.
Rutgeerts P
Gut; 1999 Jul; 45(1):13-4. PubMed ID: 10498451
[No Abstract] [Full Text] [Related]
2. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Crohn's disease at the turn of the century.
Bickston SJ; Cominelli F
N Engl J Med; 1998 Aug; 339(6):401-2. PubMed ID: 9691110
[No Abstract] [Full Text] [Related]
4. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Feagan BG; Sandborn WJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
[TBL] [Abstract][Full Text] [Related]
5. A comparison of budesonide and mesalamine for active Crohn's disease.
Lowry PW; Sandborn WJ
Gastroenterology; 1999 May; 116(5):1263. PubMed ID: 10220523
[No Abstract] [Full Text] [Related]
6. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
Sandborn WJ; Feagan BG
Aliment Pharmacol Ther; 2003 Aug; 18(3):263-77. PubMed ID: 12895211
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of budesonide therapy for Crohn's disease.
Kane SV; Schoenfeld P; Sandborn WJ; Tremaine W; Hofer T; Feagan BG
Aliment Pharmacol Ther; 2002 Aug; 16(8):1509-17. PubMed ID: 12182751
[TBL] [Abstract][Full Text] [Related]
8. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
[TBL] [Abstract][Full Text] [Related]
10. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
11. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
[TBL] [Abstract][Full Text] [Related]
12. Budesonide in the treatment of Crohn's disease: a meta-analysis.
Papi C; Luchetti R; Gili L; Montanti S; Koch M; Capurso L
Aliment Pharmacol Ther; 2000 Nov; 14(11):1419-28. PubMed ID: 11069312
[TBL] [Abstract][Full Text] [Related]
13. Budesonide for induction of remission in Crohn's disease.
Otley A; Steinhart AH
Cochrane Database Syst Rev; 2005 Oct; (4):CD000296. PubMed ID: 16235274
[TBL] [Abstract][Full Text] [Related]
14. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
Tromm A; Bunganič I; Tomsová E; Tulassay Z; Lukáš M; Kykal J; Bátovský M; Fixa B; Gabalec L; Safadi R; Kramm HJ; Altorjay I; Löhr H; Koutroubakis I; Bar-Meir S; Stimac D; Schäffeler E; Glasmacher C; Dilger K; Mohrbacher R; Greinwald R;
Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
[TBL] [Abstract][Full Text] [Related]
15. [Drug therapy of Crohn's disease: slowly increase or start aggressively right away?].
Bischoff A
MMW Fortschr Med; 2010 Jan; 152(1-2):20. PubMed ID: 20302159
[No Abstract] [Full Text] [Related]
16. [New therapeutic modalities in Crohn's disease].
Rachmilewitz D
Harefuah; 1999 Jun; 136(12):943-5. PubMed ID: 10955155
[No Abstract] [Full Text] [Related]
17. [For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
MMW Fortschr Med; 2009 May; 151(19):38-9. PubMed ID: 19827443
[No Abstract] [Full Text] [Related]
18. Update on the management of Crohn's disease.
Buchner AM; Blonski W; Lichtenstein GR
Curr Gastroenterol Rep; 2011 Oct; 13(5):465-74. PubMed ID: 21792543
[TBL] [Abstract][Full Text] [Related]
19. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults.
McKeage K; Goa KL
Drugs; 2002; 62(15):2263-82. PubMed ID: 12381231
[TBL] [Abstract][Full Text] [Related]
20. Treatment of joint pain in Crohn's patients with budesonide controlled ileal release.
Florin TH; Graffner H; Nilsson LG; Persson T
Clin Exp Pharmacol Physiol; 2000 Apr; 27(4):295-8. PubMed ID: 10779128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
